Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Letrozole 2.5mg tablets
0803041L0AAAAAA
|
Letrozole | Letrozole | Malignant Disease and Immunosuppression | 271,303 |
|
Anastrozole 1mg tablets
0803041B0AAAAAA
|
Anastrozole | Anastrozole | Malignant Disease and Immunosuppression | 139,760 |
|
Tamoxifen 20mg tablets
0803041S0AAABAB
|
Tamoxifen citrate | Tamoxifen citrate | Malignant Disease and Immunosuppression | 118,218 |
|
Azathioprine 50mg tablets
0802010G0AAAEAE
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 92,166 |
|
Prostap 3 DCS 11.25mg inj pre-filled syringes
0803042N0BBADAD
|
Prostap | Leuprorelin acetate | Malignant Disease and Immunosuppression | 49,255 |
|
Exemestane 25mg tablets
0803041C0AAAAAA
|
Exemestane | Exemestane | Malignant Disease and Immunosuppression | 46,123 |
|
Azathioprine 25mg tablets
0802010G0AAADAD
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 45,389 |
|
Mycophenolate mofetil 500mg tablets
0802010M0AAABAB
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 37,330 |
|
Bicalutamide 50mg tablets
0803042A0AAAAAA
|
Bicalutamide | Bicalutamide | Malignant Disease and Immunosuppression | 35,808 |
|
Zoladex LA 10.8mg implant SafeSystem pre-filled syringes
0803042K0BBABAB
|
Zoladex | Goserelin acetate | Malignant Disease and Immunosuppression | 31,284 |
|
Zoladex 3.6mg implant SafeSystem pre-filled syringes
0803042K0BBAAAA
|
Zoladex | Goserelin acetate | Malignant Disease and Immunosuppression | 26,948 |
|
Decapeptyl SR 11.25mg inj vials
0803042W0BBAAAA
|
Decapeptyl | Triptorelin | Malignant Disease and Immunosuppression | 24,709 |
|
Bicalutamide 150mg tablets
0803042A0AAABAB
|
Bicalutamide | Bicalutamide | Malignant Disease and Immunosuppression | 24,708 |
|
Hydroxycarbamide 500mg capsules
0801050P0AAAAAA
|
Hydroxycarbamide | Hydroxycarbamide | Malignant Disease and Immunosuppression | 18,497 |
|
Leuprorelin 11.25mg inj pre-filled syringes
0803042N0AAADAD
|
Leuprorelin acetate | Leuprorelin acetate | Malignant Disease and Immunosuppression | 17,288 |
|
Mercaptopurine 50mg tablets
0801030L0AAAAAA
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 16,101 |
|
Goserelin 10.8mg implant pre-filled syringes
0803042K0AAABAB
|
Goserelin acetate | Goserelin acetate | Malignant Disease and Immunosuppression | 14,514 |
|
Prostap SR DCS 3.75mg inj pre-filled syringes
0803042N0BBACAC
|
Prostap | Leuprorelin acetate | Malignant Disease and Immunosuppression | 12,338 |
|
Goserelin 3.6mg implant pre-filled syringes
0803042K0AAAAAA
|
Goserelin acetate | Goserelin acetate | Malignant Disease and Immunosuppression | 11,477 |
|
Degarelix 80mg inj vials
0803042R0AAAAAA
|
Degarelix | Degarelix | Malignant Disease and Immunosuppression | 10,075 |
|
Mycophenolate mofetil 250mg capsules
0802010M0AAAAAA
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 9,894 |
|
Cyproterone 50mg tablets
0803042E0AAAAAA
|
Cyprote acetate (Prostate) | Cyproterone acetate | Malignant Disease and Immunosuppression | 7,813 |
|
Prograf 1mg capsules
0802020T0BBABAB
|
Prograf | Tacrolimus | Malignant Disease and Immunosuppression | 7,647 |
|
Decapeptyl SR 22.5mg inj vials
0803042S0BCAAAB
|
Decapeptyl (embonate) | Triptorelin embonate | Malignant Disease and Immunosuppression | 6,812 |
|
Decapeptyl SR 3mg inj vials
0803042P0BBAAAA
|
Decapeptyl (Prostate) | Triptorelin acetate | Malignant Disease and Immunosuppression | 6,234 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.